Aztreonam is a novel monocyclic beta-lactam antibiotic with excellent activity against a broad range of gram-negative aerobic bacteria, including Pseudomonas aeruginosa (3, 13) . The frequency of gram-negative infections in neonates and infants (9) and the problems associated with treating such infections with broad-spectrum antimicrobial agents (6) make aztreonam of special interest in pediatric therapeutics. This led us to study the pharmacokinetics of aztreonam in selected pediatric patients, and the results are recorded in this report.
MATERIALS AND 
METHODS
Subjects. All 29 subjects included in this study (Table 1 ) were inpatients at the Oklahoma Teaching Hospitals during, and for at least 48 h after, aztreonam administration. Each was receiving concurrent therapy, including antibiotics, for suspected or proven infection. Before the study, each patient's medical history was recorded, and a physical examination and battery of laboratory tests were performed. Subjects with a history of allergy to beta-lactam drugs or with abnormal hepatic or renal function were excluded. The parent(s) of each subject gave written informed consent for the child's participation after the study protocol had been explained. The study protocol was approved by the Institutional Review Board of the Oklahoma University Health Sciences Center.
Drug administration. Each subject received 30 mg of aztreonam per kg intravenously over 3 min into an indwelling intravenous catheter or needle. If the calculated dose was more than 100 mg, it was rounded to the nearest 10 mg. Aztreonam was formulated with L-arginine as a buffering agent in a ratio of 1,000 mg of aztreonam to 780 mg of Larginine. Each single-dose vial was reconstituted with 8.7 ml of sterile water to a final volume of 10 ml (100 mg/ml).
Safety evaluation. The following studies were done for each subject before and 48 h after drug administration: history, physical examination, hemogram, urinalysis, and serum chemistry profile (glucose, urea nitrogen, creatinine, electrolytes, bilirubin, alkaline phosphatase, and alanine aminotransferase). If possible, studies were also done for (10) . Serum samples obtained 15 min and 6 h after drug administration were also assayed microbiologically to determine the inhibitory and killing power of aztreonam in serum. Stock organisms resistant to other antimicrobial agents the patient was receiving were used to standardize these results. Three different bacteria, each an Escherichia coli strain with an aztreonam MIC of 0.12 ,ug/ml, were used at an inoculum of 5 x 105 CFU/ml. None of these strains-was synergistically inhibited by the combination of aztreonam with the other antimicrobial agents (ampicillin, chloramphenicol, and gentamicin). The microtiter broth method was used to measure the inhibitory power, and 0.01 ml was subcultured onto antibiotic-free agar to determine the bactericidal (killing) power (1) .
Pharmacokinetic methods. Data on the concentration of aztreonam in serum were analyzed by moment analysis (4).
The elimination rate constant, X2, was derived from fitting a Vegas, Nev., abstr. no. 410, 1983). These drug concentrations in CSF should be adequate for the treatment of meningitis caused by gram-negative bacteria, except for Pseudomonas, as they were 10 to 100 times the tnean MICs of aztreonam against Enterobacteriaceae, Haemophilus spp., and Neisseria spp. More CSF data are required, but in the presence of significant central nervous system inflammation, the concentration in CSF appeared to be comparable to or greater than that of other beta-lactams (8) .
The agreement between the results of high-pressure liquid chromatography and microbiological assays for aztreonam lends additional evidence for extrapolating these data from in vitro activity to in vivo efficacy. The results also confirm the bactericidal activity of aztreonam, an important factor in the therapy of serious infections.
The single 30-mg/kg dose of aztreonam used in this study was well tolerated. The patients with mild to moderate eosinophilia showed no evidence of more generalized allergic or hypersensitivity reactions; concurrent infections or drug therapy may have contributed to the eosinophilia. These data lend additional support to the favorable therapeutic-to-toxic effect ratio of aztreonam noted in studies with animals (5) and adult humans (11) .
This study of the pharmacokinetics and safety of singledose administration suggests that aztreonam may prove to be a safe, effective antimicrobial agent in the treatment of serious gram-negative infections in children. The concentrations in urine and CSF and the microbiological activity in serum support further investigation of aztreonam in multiple-dose clinical trials in children. 
